16 September 2026 editorial review · Item
OZTx-410 allogeneic iPSC islet cell sheet (Orizuru): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: The Japanese jRCT record confirms OZT-410 is not recruiting, with three planned recipients aged 20 to under 65. That status does not demonstrate insulin independence or efficacy.
- Programme/sponsor/conference source boundary: Phase 1/1b trial to evaluate the safety of OZTx-410, allogeneic iPS cell derived islet cell sheet in individuals with type 1 diabetes eligible for pancreatic islet transplantation (OASiS-1; jRCT2053240146) (registry).